CD79B and B-cell non-Hodgkin lymphoma: The successful use of minimal and residual material from cytological samples allied to an innovative high-throughput multiplex platform for finding EZH2 and CD79B mutations in patients with B-cell NHL exponentially increases the availability of specimens for clinical analysis and may lead to an increase in the number of patients eligible for clinical trials.